news, journals and articles from all over the world.
Researchers in Italy have identified a pair of microRNA molecules that help maintain a population of cancerous stem cells that drive the growth of breast cancers and initiate tumor relapse after treatment. The study, which will be published April 2 in the Journal of Cell Biology (JCB), reveals that targeting these microRNAs makes cancer stem cells more susceptible to some chemotherapies and could potentially improve the prognosis of patients with aggressive forms of breast cancer.
World-first 3D printed oesophageal stents developed by the University of South Australia could revolutionise the delivery of chemotherapy drugs to provide more accurate, effective and personalised treatment for patients with oesophageal cancer.
There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.
Marie Mclaughlin, MSc, from Edinburgh Napier University in Scotland, will present research on human endothelial cells treated with FEC-T, a chemotherapy regimen that combines four drugs (5 fluorouracil, epirubicin, cyclophosphamide and docetaxel). The researchers found that preconditioning the endothelial cells with serum (blood) from people who habitually exercise caused less cell death than samples that were treated with untrained serum (people who exercised less than 75 minutes per week). “Exercise preconditioning can provide protection against these detrimental effects in vitro,” Mclaughlin explained.
A research team led by Jared Dickinson, PhD, from Central Washington University, followed people with breast cancer who were treated with anthracycline-containing chemotherapy.
Cancer is the second leading cause of death around the world after heart disease. This week, researchers exploring the effects of exercise as a natural preventive tool and noninvasive treatment for cancer will present their work at the American Physiological Society (APS) Integrative Physiology of Exercise conference.
Atlantic Health System has announced the opening of Morristown Medical Center’s new state-of-the-art, patient-centered Infusion Center located in the Carol G. Simon Cancer Center. The first of three phases of expansion of New Jersey’s pre-eminent cancer center, the new unit was funded in large part by donations made by community members in support of the Foundation for Morristown Medical Center’s Growing Forward Campaign.
Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering.
A research team from Mount Sinai has unraveled for the first time the three-dimensional structure and mechanism of a complex enzyme that protects cells from constant DNA damage, opening the door to discovery of new therapeutics for the treatment of chemotherapy-resistant cancers.
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone. In a nationwide analysis of nearly 20,000 patients whose cancer had not yet spread to other organs, the scientists learned that only 22% were treated with some form of chemotherapy.
For younger cancer patients, fertility counseling at the time of cancer diagnosis is important for making family planning decisions. Ranjith Ramasamy, M.D., a clinician and researcher at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, was the lead author of a new collaborative study, “Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey,” published JAMA Network Open.
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.
Research news from Johns Hopkins Medicine.
Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for cancer patients.
Chemotherapy has been the lone suspect in a neurological ailment, but cancer may be also to blame. The havoc they wreak is much more than additive.
A new University of Kentucky Markey Cancer Center study finds that many Kentucky patients with colon cancer are not receiving the recommended standard of care therapy for their disease.
As the height of the COVID-19 outbreak in New York City and the Tri-State area begins to subside, Memorial Sloan Kettering Cancer Center oncologists are urging patients to schedule cancer screenings and treatments now – as the long-term toll of missed diagnoses and delayed treatments could be devastating for patients and their loved ones across the region and the country.
A clinical trial led by Mount Sinai researchers has showed for the first time that combining chemotherapy and immunotherapy can slow down metastatic bladder cancer. The trial also showed that immunotherapy alone may be an option for a subset of patients with metastatic bladder cancer if their tumor expresses a high level of a protein called PD-L1 according to the study, published in The Lancet in May.
Using immunotherapy immediately after chemotherapy treatment in patients with metastatic bladder cancer significantly slowed the progression of the cancer, according to results of a clinical trial led by Mount Sinai researchers published in the Journal of Clinical Oncology in April.
Keck Medicine of USC study reveals that non-small cell lung cancer patients with pathologic N1 disease were less likely to receive chemotherapy if they lived in rural areas or were on Medicaid or uninsured.
Two scientists from Wake Forest School of Medicine, part of Wake Forest Baptist Health, have received a total of $1.5 million in research funding from the American Cancer Society (ACS) to study new chemotherapy and immunotherapy treatments for cancer.
Each year, more than 250,000 women in the U.S. alone receive a diagnosis of breast cancer, making it the most commonly diagnosed cancer among women. More than 40,000 women annually die from the disease, according to the American Cancer Society.
Virtual Reality during chemotherapy shown to improve breast cancer patients’ quality of life during the most stressful treatments, according to a recent study.
Virtual Reality during chemotherapy shown to improve breast cancer patients’ quality of life during the most stressful treatments, according to a recent study.
A Mayo Clinic study involving 5,540 patients with metastatic colorectal cancer finds that maintenance chemotherapy after initial treatment is more beneficial for patients whose disease is under control, compared with more aggressive treatment.
In a new study, scientists observed several simultaneous reactions in mice given a common chemotherapy drug: Their gut bacteria and tissue changed, their blood and brains showed signs of inflammation, and their behaviors suggested they were fatigued and cognitively impaired.
After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.
Study in JNCCN—Journal of the National Comprehensive Cancer Network, finds early dose reduction of adjuvant FEC-D chemotherapy negatively impacts overall survival rates for women with intermediate- or high-risk breast cancer.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu